FDA approves Tremfya for pediatric plaque psoriasis, active psoriatic arthritis

The U.S. Food and Drug Administration has approved Johnson & Johnson’s Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 years of age and older.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup